Sensus Healthcare to Participate in the 36th Annual Roth Conference
Sensus Healthcare to Participate in the 36th Annual Roth Conference
Management will discuss its new "Fair Deal Agreement" for its SRT-100 Vision IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th
BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional investors at the 36th Annual Roth conference to be held March 17th – 19th in Dana Point, Calif.
During the meetings, management will discuss its new Fair Deal Agreement program, which provides an additional economic value proposition to customers and a recurring revenue model for Sensus. Management will also discuss the reception it received at its booth at the American Academy of Dermatology Annual Meeting earlier this month, as described in its recently issued press release.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings.
Management will discuss its new "Fair Deal Agreement" for its SRT-100 Vision IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th
管理層將於3月18日和19日在加利福尼亞州達納波因特舉行的一對一會議上討論其 SRT-100 Vision IG-SRT 的新 “公平交易協議”
BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces management will participate in one-on-one or small group meetings with institutional investors at the 36th Annual Roth conference to be held March 17th – 19th in Dana Point, Calif.
佛羅里達州博卡拉頓，2024年3月14日（GLOBE NEWSWIRE）——專門爲腫瘤和非腫瘤疾病提供高效、無創、微創和具有成本效益治療的醫療器械公司Sensus Healthcare, Inc.（納斯達克股票代碼：SRTS）宣佈，管理層將在3月17日至19日在加利福尼亞州達納波因特舉行的第36屆年度羅斯會議上參加與機構投資者的一對一或小組會議。
During the meetings, management will discuss its new Fair Deal Agreement program, which provides an additional economic value proposition to customers and a recurring revenue model for Sensus. Management will also discuss the reception it received at its booth at the American Academy of Dermatology Annual Meeting earlier this month, as described in its recently issued press release.
會議期間，管理層將討論其新的公平交易協議計劃，該計劃爲客戶提供了額外的經濟價值主張，併爲Sensus提供了經常性收入模式。正如其最近發佈的新聞稿中所述，管理層還將在本月早些時候的美國皮膚科學會年會上討論其在展位上受到的接待。
About Sensus Healthcare
關於 Sensus 醫療保健
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings.
Sensus Healthcare, Inc. 是開發和提供皮膚癌和瘢痕瘤非侵入性治療的全球先驅。該公司利用其尖端的淺表放射治療（SRT和IG-SRT）技術，爲醫療保健提供商提供高效的、以患者爲中心的治療平台。Sensus Healthcare 致力於推動放射腫瘤學創新，提供安全、精確且可適應各種臨床環境的解決方案。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧